SCHEMBL2128166

SCHEMBL2128166

Cc1cc(Cl)nc(Cl)c1C(=O)NCc1ccc(F)cc1

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.81
MEN1 O00255 3/20 0.81
ALDH1A1 P00352 2/20 0.58
TAAR1 Q96RJ0 1/20 0.58
GAA P10253 1/20 0.58
TSHR P16473 1/20 0.58
KCNQ3 O43525 1/20 0.58
KCNQ2 O43526 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.50
HTT P42858 1/20 0.50
THRB P10828 1/20 0.50
POLB P06746 1/20 0.50
ATM Q13315 1/20 0.50
TP53 P04637 1/20 0.49
HSD17B10 Q99714 1/20 0.48
NPC1 O15118 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CHRM4 P08173 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128569 0.89 KMT2A (1.00) KMT2AMEN1ALDH1A1TAAR1TSHR
SCHEMBL2130294 0.88 KMT2A (0.70) KMT2AMEN1ALDH1A1TAAR1GAA
SCHEMBL2129852 0.86 MEN1 (0.67) KMT2AMEN1ALDH1A1TAAR1SMN1; SMN2
SCHEMBL2131055 0.85 KMT2A (0.59) KMT2AMEN1ALDH1A1TAAR1GAA
SCHEMBL6257633 0.83 KMT2A (0.56) KMT2AMEN1ALDH1A1GAATSHR
SCHEMBL6263056 0.77 SMN1; SMN2 (0.51) KMT2AMEN1ALDH1A1GAATSHR
SCHEMBL2129169 0.76 KMT2A (0.75) KMT2AMEN1ALDH1A1TAAR1TSHR
SCHEMBL6259709 0.76 KCNQ3 (0.52) KMT2AMEN1ALDH1A1GAATSHR
SCHEMBL2132876 0.75 KMT2A (0.47) KMT2AMEN1ALDH1A1GAATSHR
SCHEMBL2129613 0.75 MEN1 (0.53) KMT2AMEN1ALDH1A1TAAR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3318556-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2018-05-09 EP disclosed
EP-2630123-B1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS GRUENENTHAL GMBH (DE) 2017-12-20 EP disclosed
US-9278103-B2 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators Grünenthal GmbH (DE) 2016-03-08 US disclosed
US-9168259-B2 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators Grünenthal GmbH (DE) 2015-10-27 US disclosed
US-20140213569-A1 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators GRUNENTHAL GMBH (DE) 2014-07-31 US disclosed
US-8552200-B2 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-10-08 US disclosed
EP-2630123-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2013-08-28 EP disclosed
US-20120258947-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2012-10-11 US disclosed
US-20120101079-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2012-04-26 US disclosed
WO-2012052167-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213569-A1 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators KCNQ2, KCNQ1, KCNQ3 KMT2A 403/4885MEN1 3018/4885ALDH1A1 2214/4885
US-20120101079-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS KCNQ2, KCNQ1, KCNQ3 KMT2A 403/4885MEN1 3018/4885ALDH1A1 2214/4885
US-20120258947-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS KCNQ2, KCNQ1, KCNQ3 KMT2A 403/4885MEN1 3018/4885ALDH1A1 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.